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With promising results in recent treatment trials for Alzheimer’s disease (AD), it
becomes increasingly important to distinguish AD at early stages from other causes
for cognitive impairment. However, existing diagnostic methods are either invasive
(lumbar punctures, PET) or inaccurate Magnetic Resonance Imaging (MRI). This study
investigates the potential of neuropsychological testing (NPT) to specifically identify
those patients with possible AD among a sample of 158 patients with Mild Cognitive
Impairment (MCI) or dementia for various causes. Patients were divided into an early
stage and a late stage group according to their Mini Mental State Examination (MMSE)
score and labeled as AD or non-AD patients based on a post-mortem validated
threshold of the ratio between total tau and beta amyloid in the cerebrospinal fluid (CSF;
Total tau/Aβ(1–42) ratio, TB ratio). All patients completed the established Consortium to
Establish a Registry for Alzheimer’s Disease—Neuropsychological Assessment Battery
(CERAD-NAB) test battery and two additional newly-developed neuropsychological
tests (recollection and verbal comprehension) that aimed at carving out specific
Alzheimer-typical deficits. Based on these test results, an underlying AD (pathologically
increased TB ratio) was predicted with a machine learning algorithm. To this end,
the algorithm was trained in each case on all patients except the one to predict
(leave-one-out validation). In the total group, 82% of the patients could be correctly
identified as AD or non-AD. In the early group with small general cognitive impairment,
classification accuracy was increased to 89%. NPT thus seems to be capable of
discriminating between AD patients and patients with cognitive impairment due to
other neurodegenerative or vascular causes with a high accuracy, and may be used
for screening in clinical routine and drug studies, especially in the early course of this
disease.
Keywords: Alzheimer’s disease, MCI, total tau to Aβ(1–42) ratio, neuropsychological testing, dementia, machine
learning
Abbreviations: Aβ(1–42), Beta-Amyloid(1–42); AD, Alzheimer’s Disease; CERAD-NAB, Consortium to Establish a Registry
for Alzheimer’s Disease—Neuropsychological Assessment Battery; MCI, Mild Cognitive Impairment; MMSE, Mini Mental
Status Examination; MRI, Magnetic Resonance Imaging; NPT, Neuropsychological Testing; PCA, Principal Component
Analysis; SVC, Support Vector Classifier; TB ratio, Total tau/Aβ(1–42) ratio; TBpm ratio, Total tau/Aβ(1–42) ratio of 0.721
post-mortem verified by Tapiola et al. (2009).
Frontiers in Aging Neuroscience | www.frontiersin.org 1 April 2017 | Volume 9 | Article 114
Gurevich et al. Neuropsychological Testing Detects Alzheimer’s Disease
INTRODUCTION
While the global number of patients with Alzheimer’s disease
(AD) is increasing, recent clinical trials suggest for the first time
the possibility of devising a disease-modifying treatment (among
others, Sevigny et al., 2016). The early detection and differential
diagnosis of AD is herefore becoming an urgent task. One early
biomarker of AD is the ratio of the concentrations of total tau
protein and beta amyloid (1–42), Aβ(1–42) in the cerebrospinal
fluid (CSF; Frankfort et al., 2008; Hertze et al., 2010; van Rossum
et al., 2010). A recent study demonstrated that these two proteins
are the most important and earliest biomarkers for AD, even
compared to PET (Palmqvist et al., 2016). However, since a
lumbar puncture is an invasive and sometimes contraindicated
method, it is crucial to develop valid and risk-free alternative
methods for the diagnosis of AD.
Specific neuropsychological testing (NPT) might represent
such a method, with a substantial body of evidence
demonstrating its potential for differential diagnosis (Edmonds
et al., 2015; Haanpää et al., 2015; Mansoor et al., 2015) and
prognosis estimation (Landau et al., 2010; Peters et al., 2014).
For identifying AD patients diagnosed by clinical criteria, it
yielded an accuracy similar to CSF biomarkers (Schmand et al.,
2010) and could predict the development of AD as early as
10 years before the clinical syndrome has developed (Boraxbekk
et al., 2015; Mistridis et al., 2015). Moreover, since specific
impairments in AD patients such as an increased number of
false positives during recognition of semantically related or
prototypical visual items (Gallo et al., 2004; Gold et al., 2007;
Hildebrandt et al., 2009) are hitherto not covered by standard
testing, the potential of NPT might not yet be fully deployed.
While it thus seems that NPT might contribute to a risk-free
early diagnosis of AD, it should be validated with established
biomarkers like Aβ(1–42) and tau protein to reduce the risk
of circular reasoning in predicting clinical diagnoses based
on clinical neuropsychological assessments (Haldenwanger
et al., 2010; Fields et al., 2011; Nelson et al., 2012, for previous
work on relationships between NPT results and non-clinical
biomarkers).
Furthermore, modern machine learning techniques have
up to now only very rarely been used for the differential
diagnosis of dementia based on the results of specific
neuropsychological tests. However Klöppel et al. (2008)
reported an effective differentiation between Alzheimer’s
and frontotemporal dementia based on Magnetic Resonance
Imaging (MRI) scans and machine learning and Wang et al.
(2016) compared NPT and MRI scans as predictors for a
machine-learning based distinction between Alzheimer’s
and behavioral frontotemporal dementia. In general, these
algorithms learn which specific neuropsychological deficit
patterns are typical of AD patients in a training sample
and then use these learned regularities to predict the AD
status of new independent patients. During training, the
algorithm is ‘‘blind’’ for the patient to be predicted and
instead learns on all patients except the one to predict
(leave-one-out technique). Thus, contrary to conventional
analysis methods where the predicted cases are part of the
training set, this approach resembles the clinical situation,
in which the underlying pathology of a new patient has to
be inferred based on his/her NPT results, arguably rendering
the resultant predictions more meaningful (Lo et al., 2015).
In the present study, we used the so-called ‘‘support vector
classifier’’ (SVC), an established and powerful machine learning
algorithm (Cristianini and Shawe-Taylor, 2000), for this
purpose. Simplified, a SVC finds a separating hyperplane in the
higher-dimensional data space (in our case, the NPT results)
such that the classes (diagnoses) are separated with a maximal
distance.
As outlined above, the main question of the present study was
whether using more specific neuropsychological test batteries
combined with machine learning might help to detect AD
patients as defined by biomarkers, not by clinical criteria, and
in a predictive manner (i.e., while separating training and test
cases). To test the feasibility of this approach for a wide range
of cognitive impairment severities, we included patients with
minimal cognitive impairment (Mini Mental State Examination
(MMSE) score lower than 29 but higher than 24) up until
manifest dementia (MMSE score 24 and lower) and defined
the presence of AD by a pathological Total tau/Aβ(1–42)
ratio (TB ratio) in the CSF, which is still the most sensitive
and specific biomarker for AD (Tapiola et al., 2009; Hertze
et al., 2010; Palmqvist et al., 2016). This approach is in
line with recently published research criteria, stating that the
combination of cognitive impairment plus positive biomarker
pattern confirms the diagnosis of a possible AD (Dubois
et al., 2014). Separately for early patients with small cognitive
impairment, late patients with marked cognitive impairment
and the total sample comprising both groups, we assessed the
predictive performance of machine learning based on standard
and extended (‘‘full’’) NPT.
PATIENTS AND METHODS
Patients
We recruited 158 inpatients with cognitive impairment from the
neurological department of the hospital of Bremen-Ost. Patients
with acute neurological causes for impairment (i.e., stroke
or inflammatory diseases) were not included. To test if the
diagnostic power of our approach might depend on the severity
of cognitive impairment, we divided patients into an early
group with MMSE scores between 25–28 and a late group with
MMSE scores below 25 and report results separately for the
two subgroups (alongside with the total group comprising all
patients).
Demographic details andCSF biomarker values of the patients
are summarized in Table 1. Patients were defined as AD patients
according to the TB ratio in the CSF. For this purpose, we
used the TBpm ratio of 0.721 published by Tapiola et al. (2009;
in line with this study, patients with a ratio above this TBpm
ratio were labeled as AD patients). According to Tapiola et al.
(2009) the accuracy of the TBpm ratio in predicting post-mortem
analyzed neuropathology of AD is 85.4% with a specificity of
89.3% and a sensitivity of 84.2%. Based on these diagnostic labels,
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TABLE 1 | Demographic information and results of cerebrospinal fluid analysis for the patients’ samples.
Early group (MMSE 25–28) Late group (MMSE 8–24)
Number of patients 89 69
Sex∗ Female: 30, Male: 59 Female: 42, Male: 27
Number of patients with AD according to their TB
ratio
AD: 23, non-AD: 66 AD: 47, non-AD: 22
Mean SD Mean SD
Age (years) 69.8 7.4 71.4 6.8
Education 12.9 2.2 12.4 2.3
Total tau∗ 384.2 224.4 642.1 549.0
Aβ(1–42)∗ 788.5 317.7 518.9 233.5
Tau/Aβ(1–42) ratio∗ 0.61 0.55 1.65 1.71
Mini Mental Status Examination score∗ 26.4 1.1 19.7 4.3
Beck’s Depression Inventory score 9.8 8.1 10.6 8.4
∗Significant (p< 0.05) difference between early and late group (chi-squared test for sex, t-test for all other variables). Abbreviations: MMSE, Mini Mental Status Examination;
TBpm, Total tau/Aβ(1–42) ratio verified by Tapiola et al. (2009).
Table 1 also indicates which of the demographic and biomarker
characteristics differed significantly between AD and non-AD
patients.
Of the 158 patients, 89 patients had a MMSE score between
25–28 (early group), and 69 patients between 8–24 (late
group). Patients in the early group showed significantly higher
Aβ(1–42) concentrations and lower total tau concentrations
than patients in the late group (Table 1), but they did not
differ in age, education and depressive mood. There was a
significant difference in sex with female patients prevailing in
the late group and male patients in the early group. Because
of this difference and due to well-known gender-dependent
effects in verbal and non-verbal cognitive abilities, we always
performed classification separately for male and female patients
(see below).
The study was approved by the Ethics committee of the
University of Oldenburg and patients gave their informed
consent to participate in the study.
Neuropsychological Investigation
All patients underwent a neuropsychological examination,
including the Consortium to Establish a Registry for Alzheimer’s
Disease—Neuropsychological Assessment Battery (CERAD-
NAB) test battery, which is standard for dementia testing and
comprises a short version of the Boston Naming Test, semantic
word fluency test, word list learning, figure copying and delayed
figure recall (Morris et al., 1988, 1989). Moreover, the digit
span from the Wechsler Memory Scale (Wechsler, 1987) was
used to investigate verbal working memory performance and the
Beck Depression Inventory (Beck and Bailer, 1985) to measure
depressive symptoms.
Additionally, we carried out two newly developed
neuropsychological tests aiming to capture cognitive
impairments specific for AD patients. First, previous studies
(Gold et al., 2007; Hildebrandt et al., 2009; Haldenwanger
et al., 2010) have consistently demonstrated that specifically
AD patients are suggestible for visually prototypical items
and tend to rate them as already presented. To carve out this
deficit, patients were first asked to name 16 pictures without
knowing that they would later be asked to recognize them.
After 15 min, 24 recognition trials were carried out. Each of
these trials encompassed three pictures that stemmed from the
same category to increase discrimination difficulty. Twelve of
these triplets comprised pictures with biological content (eight
triplets of animals, three triplets of body organs and one triplet
with fruits), the other 12 triplets showed man-made items
like vehicles, furnishings and instruments. As far as possible,
the pictures were similar in their geometrical shape. We also
ensured that the familiarity (frequency of use) of the target item
was not higher than that of the two distractor items. Whereas
sixteen of these recognition trials in fact comprised one of the
initially shown pictures, eight of them only consisted of new
pictures, increasing the probability of falsely positive responses.
In each trial, the participants had to decide whether one of
the three pictures had been shown before, and if so, which
one. Based on our prior work (Hildebrandt et al., 2009), we
expected that an increased number of false positives in this task
would help to distinguish AD from other causes for cognitive
impairment.
Second, AD patients show impairment in memory function
but not in verbal understanding, which is typically impaired in
frontotemporal and subcortical dementia (Rohrer et al., 2008).
We therefore tested comprehension by giving the patients six
written sets of instructions for constructional tasks (i.e., ‘‘draw
a square, inside the square a circle and inside the circle a cross’’)
and counting the number of correct drawings (with a range from
0 to 6 correct solutions). The order of the six tasks was always the
same and determined by their difficulty. Here, we expected that
a comparatively intact functioning in this task should delineate
AD patients from other causes.
Neurological Investigation
The neurological investigation served to exclude acute causes for
cognitive impairment and included medical history, physical and
neurological examination, laboratory blood tests, brain imaging,
electroencephalography and a lumbar puncture.
The blood sample analysis comprised blood count,
erythrocyte sedimentation rate, electrolytes, creatinine, urea,
transaminases, blood glucose, TSH, C-reactive protein, vitamin
B 12 and folic acid.
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Determination of tau Protein and Aß(1–42)
Lumbar punctures were performed during the same hospital stay
as the NPT and carried out by a trained neurologist, using a
22-gauge Sprotte spinal needle. Approximately 5 ml CSF were
taken. CSF samples were collected in polypropylene tubes and
transported to an adjacent laboratory within 30min. CSF samples
were analyzed for cell count, total protein, lactate, glucose, IgG,
IgA, IgM, borreliose antibodies, Aβ(1–42) and total tau protein.
Total tau was determined using a commercial sandwich enzyme-
linked immunosorbent assay and Aβ(1–42) using a sandwich
ELISA (Innotestr hTAU-Ag and Innotestr β-amyloid (1–42),
respectively, Innogenetics, Belgium). All tests were performed at
the Medizinisches Labor Bremen.
Classification Procedure
Themain goal of our study was to predict if cognitive impairment
in a single patient is due to AD or other causes based on
specific patterns of neuropsychological test results that have
to be inferred by the algorithm from the remaining patients
without the patient to be predicted. To this end, we used the
SVC (Cristianini and Shawe-Taylor, 2000), in a leave-one-out
procedure comprising the following steps:
1. Assign objective diagnostic labels to N patients: a patient
belongs to class 1 (AD patients) if the TB ratio is greater than
the post-mortem validated TBpm ratio.
2. Remove the to-be-predicted patient from the data (leave-
one-out): for the i-th patient from the target subgroup
(i = 1,. . ., N): remove from the data matrix X the i-th row
corresponding to the i-th patient.
3. Preprocessing of the data (normalization and feature
reduction): normalize the resulting matrix Xi by centering
each column to its mean and scaling to unit variance; apply
principal component analysis (PCA, feature reduction) to Xi.
4. Train the algorithm on the data set without the to-be-
predicted patient: fit the SVC, using Xi. In order to avoid
artificially high accuracy values in the case of an unbalanced
number of cases per class (i.e., to avoid a high sensitivity
at the expense of poor specificity or vice versa (Nguyen
et al., 2009)), the algorithm was trained to obtain a maximal
harmonic mean between sensitivity and specificity. The
harmonic mean between sensitivity and specificity is defined
as 2∗sensitivity∗specificity/(sensitivity + specificity).
5. Predict the patient: apply the transformations from step 3 to
the row corresponding to the i-th patient; predict with the
fitted SVC to which class the i-th patient belongs.
6. Repeating step 2–5 for all i = 1,. . ., N and comparing the
prediction with the pre-classification from step 1, find the
confusion matrix for the target subgroup of N patients.
The leave-one-out algorithm was employed with the
explained variance of the PCA E = 0.7, 0.8, 0.9, 0.99, 1. We used
the E that yielded the maximal harmonic mean of sensitivity
and specificity. As explained above (see paragraph ‘‘Patients’’),
classification was carried out separately for male and female
patients and the results reported below refer to the pooled
outcomes of both sexes.
Classification Superiority over
Conventional Testing
Additionally to obtaining absolute classification accuracies, we
aimed at demonstrating that AD could superiorly be delineated
from other causes for cognitive impairment when the new
specific neuropsychological tests (suggestibility for visually
prototypical items and verbal understanding as described above)
were included in the test battery. To this end, we used the
binomial test to compare the number of correctly classified
patients according to a standard neuropsychological model that
comprised gender, education, age and all CERAD-NAB scores
as predictors (standard model) with that according to the full
test battery that additionally included new tests (full model).
Note that a patient was considered as correctly classified if the
prediction of the algorithm matched the ‘‘objective’’ label based
on his/her TB ratio. This analysis thus tests if the classification
results obtained when using the full test battery including the new
tests as predictors were significantly superior to the results using
demographic variables plus standard NPT only.
RESULTS
Neuropsychological Tests Results
Table 2 shows the neuropsychological test results for the three
groups. Note that all patients were cognitively impaired, and
hence AD and non-AD groups are exclusively defined by the
TBpm ratio. Cognitive performance differed between AD and
non-AD patients depending on disease stage: in the early group,
patients with AD-like TBpm ratio scored significantly better in
language comprehension and working memory, whereas in the
late and total group, tests on memory performance showed the
typical impairments for the AD patients. These results indicate
that the most sensitive combination of neuropsychological tests
for distinguishing AD from non-AD patients depends on the
disease stage.
Classification Results
Table 3 summarizes the results of predicting the cause for
cognitive impairment of the patients (AD or non-AD defined
by the TBpm ratio), using the full battery of neuropsychological
tests (column ‘‘full’’) and using only the standard testing (column
‘‘standard’’). Classification accuracy was 82% in the total group
with better results for the early group (89%) compared to the
late group (72%). This decline in accuracy with progressing
disease was mainly due to decreasing specificity, whereas
sensitivity figures remained largely unchanged. Hence, in the
late stage, non-AD causes for cognitive decline increasingly
resemble the pattern of cognitive deficits that allowed precise




Table 3 also provides a comparison between prediction
performance based on the neuropsychological standard testing
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TABLE 2 | Neuropsychological test results of the patients’ groups.
Early group (MMSE 25–28) Late group (MMSE 8–24) Total group
Non-AD AD Non-AD AD Non-AD AD
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD
Newly developed tests
Visual recognition, omissions 2.6 2.1 2.6 2.3 3.9 3.0 3.9 3.9 3.0 2.4 3.5 3.5
Visual recognition, false positives∗,∼ 1.1 1.9 2.0 2.2 2.8 3.1 5.1 4.3 1.5 2.3 4.1 4.0
Language comprehension+,∼ 2.7 1.5 4.3 1.2 3.0 1.7 3.5 1.7 2.8 1.6 3.7 1.6
CERAD-NAB
Semantic wordfluency 13.0 4.4 15.0 4.4 10.8 5.2 9.6 4.9 12.4 4.7 11.3 5.3
Boston naming 13.0 2.3 13.6 1.6 12.3 2.0 12.5 4.1 12.8 2.2 12.8 3.6
Wordlist learning∗,∼ 13.0 3.4 13.3 4.0 10.4 2.8 8.2 4.3 12.3 3.5 9.8 4.8
Wordlist delayed recall ∗,∼ 3.8 1.9 3.3 1.6 2.4 1.7 1.4 1.5 3.5 1.9 2.0 1.8
Wordlist savings∼ 69.3 30.9 64.5 27.4 48.5 33.5 36.2 40.0 64.1 32.7 45.3 38.6
Wordlist discrimination∗,∼ 92.0 8.7 89.1 10.4 85.0 9.5 78.2 14.1 90.2 9.4 81.6 13.9
Visuoconstruction 8.9 1.8 9.4 1.8 8.8 1.8 8.6 1.9 8.9 1.8 8.8 1.9
Visuoconstruction delayed recall∼ 5.7 3.2 4.7 2.7 3.7 2.5 2.5 2.8 5.2 3.1 3.2 2.9
Visuoconstruction savings ∗,∼ 63.4 33.9 50.8 28.2 42.1 30.0 25.8 28.7 58.1 34.1 33.7 30.7
Working memory testing
Digit span forward+ 31.8 24.2 50.2 29.7 35.0 29.4 30.8 28.5 32.6 25.5 36.9 30.1
Digit span backward+ 19.7 17.9 37.9 24.7 19.3 26.2 15.3 15.4 19.6 20.1 22.5 21.5
+Early group: p < 0.05 Alzheimer’s disease (AD) vs. non-AD, two-sample t-Test. ∗Late group: p < 0.05 AD vs. non-AD, two-sample t-Test. ∼Total group: p < 0.05 AD
vs. non-AD, two-sample t-Test. Abbreviations: MMSE, Mini Mental Status Examination. With the exception of visual recognition, omissions and visual recognition, false
positives, higher values indicate a more intact functioning in the respective test.
compared to the full set with the newly developed tests.
Formal comparison using binomial tests revealed a significant
classification superiority of the full model with p < 0.001 for
the total and the early group and a trend-wise superiority in
the late group (p = 0.071). Hence, the accuracy achieved by
the full model that added new specific neuropsychological tests
was significantly better than that achieved by the standard
testing in the early and total group, and also trend-wise in the
late group.
DISCUSSION
With the advent of new treatments, early detection of AD
becomes an urgent task. We investigated the potential of NPT
to detect AD patients (defined by an AD-typical protein pattern
in the CSF) among patients with cognitive impairment caused by
various etiologies. We found that in the total group, 82% of the
patients could be correctly classified as AD or non-AD by these
means.
The accuracy of AD identification depended on disease stage
with a better accuracy (89%) for early stage patients (MMSE
25–28) compared to late stage patients (MMSE <25, 72%
accuracy). A conceivable explanation for this discrepancy might
be that the disease progress entails a more global cognitive
impairment, which may impede the detection of more specific
and fine-grained cognitive performance differences. Consistent
with this, a prior study using a similar test battery showed
that whereas Mild Cognitive Impairment (MCI) patients with
possible AD and with Parkinson’s disease differed in several
tests, fewer tests were able to distinguish between demented
AD and Parkinson’s disease patients (Hildebrandt et al.,
2013).
Part of our neuropsychological assessment was the CERAD-
NAB, a test battery frequently used in memory clinics. A recent
TABLE 3 | Sensitivity, specificity, their harmonic mean and accuracy of predicting AD (according to TB ratio) for the three MMSE groups and the two
models (full model with and standard model without newly developed tests).
Early group: MMSE 25–28 (89 patients) Late group: MMSE 8–24 (69 patients) Total group: MMSE 8–28 (158 patients)
Model Full Standard Full Standard Full Standard
Sensitivity 0.74 0.48 0.79 0.70 0.77 0.63
Specificity 0.94 0.82 0.59 0.50 0.85 0.73
Harmonic mean 0.83 0.60 0.68 0.58 0.81 0.67
Accuracy 0.89 0.73 0.72 0.64 0.82 0.68
Confusion [17 6] [11 12] [37 10] [33 14] [54 16] [44 26]
matrix [4 62] [12 54] [9 13] [11 11] [13 75] [24 64]
The confusion matrix denotes the number of patients correctly classified by Support Vector Classifier (SVC) to have AD (true positives, top/left), the number of patients
incorrectly classified by SVC to have no AD (false negatives top/right), the number of patients incorrectly classified by SVC to have AD (false positives, bottom/left) and
the number of patients correctly classified by SVC to have no AD (true negatives, bottom/right). Abbreviations: MMSE, Mini Mental Status Examination; TBpm, Total
tau/Aβ(1–42) ratio verified by Tapiola et al. (2009).
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prospective study showed that the CERAD-NAB is able to
predict the development of MCI during the next 8 years and
conversion to AD after 10 years (Mistridis et al., 2015). The
predictive power of the CERAD-NAB for diagnosis based on
clinical criteria is thus established and also a correlation of
its items (wordlist learning) with CSF biomarkers could be
shown (Haldenwanger et al., 2010). Nevertheless, in our study,
classification of biomarker-based diagnoses was significantly less
accurate using the CERAD-NAB alone than classification using
CERAD-NAB plus the newly developed tests. Thus, the newly
added assessments of language comprehension performance and
of false positives in visual recognition improved the classification
performance, speaking for the general possibility to increase
the diagnostic power of NPT by using more specific task
components.
One strength of this study is that we did not preselect for
specific cognitively impaired patients, but included patients with
various clinical diagnoses: this is a scenario which comes closest
to clinical routine and is different from previous work that
either differentiated AD dementia patients from healthy controls
(e.g., Zhang et al., 2011) or from one particular differential
diagnosis (Klöppel et al., 2008; Wang et al., 2016). Moreover,
we classified our patients exclusively by the TB ratio obtained
1–2 weeks after NPT, implying an effective blinding of the
diagnosis for the investigator. Another strength is the use of the
SVC for prediction of the patients’ status. The SVC simulates
the clinical routine situation—predicting the diagnosis of a
given patient on the background of the scientific and clinical
knowledge available up to the moment of his or her assessment.
It avoids overfitting, because the predicted patient is not part
of the training set for the model as in standard discriminant
or regression analyses and it does not presuppose normally
distributed data.
An accuracy between 75% and 89% is an encouraging result,
considering that it refers to the differential diagnosis of AD in
a sample of cognitively impaired individuals. For distinguishing
between etiologically defined dementias, the accuracy based on
CSF orMRI biomarkers alone is typically lower than these figures
(Struyfs et al., 2015; Wang et al., 2016). For the specific purpose
of identifying patients with preclinical AD, it is important to note
that classification in our early disease sample showed superior
results with an accuracy of almost 90%. Future work on potential
clinical translations of these findings could take up four different
lines of research: first, try to further improve the discriminative
power of the test battery by developing neuropsychological
tests with higher sensitivity for AD typical aspects of memory
impairment. Second, try to streamline the test battery by
removing tests that did not significantly contribute to the
predictive power and thereby facilitate the clinical application.
Third, validate the results in an independent patient collective.
Fourth, explore the synergistic potential of combinations of MRI,
lumbar puncture and NPT for a maximal accurate diagnosis
of AD. From a methodological point of view, it would be
worthwhile to also test non-linear classification techniques like
neural networks to tackle the resulting high dimensional data sets
for this purpose.
Obviously, there are also certain limitations: our study is a
single center study and the number of patients is not very large,
especially after sub-grouping. Moreover, gold standard of AD
diagnosis is the neuropathological investigation of postmortem
brain tissue that was not employed in our study. Thus, although
being in line with diagnostic guidelines (Dubois et al., 2014), our
external biomarker criterion for the diagnosis of AD was not
perfect and showed 15% disagreement with post-mortem results
in prior work (Tapiola et al., 2009). Nevertheless, our results
suggest that NPT combined with properly trained machine
learning algorithms might help to improve differential diagnosis
of AD and to preselect patients for future drug studies with a safe
and easy method.
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